Polyarthritis (erosive and non-erosive) | 183 (65.3) | 251 (89.6) | < 0.0001 |
Puffy edema of dorsal hand | 150 (53.6) | 156 (55.7) | 0.1 |
Pulmonary arterial hypertension | 0 | 50 (17.8) | — |
Raynaud phenomenon | 141 (50.3) | 161 (57.5) | 0.10 |
Myositis | 38 (13.5) | 91 (32.5) | 0.0001 |
Sclerodactyly | 99 (35.3) | 117 (41.8) | 0.1399 |
Interstitial lung disease | 2 (0.7) | 132 (47.1) | 0.0001 |
Pleuritis/pericarditis | 39 (13.9) | 83 (29.6) | 0.001 |
Nervous system disease | 35 (12.5) | 56 (20.0) | 0.02 |
Skin involvement* | 92 (32.9) | 102 (36.4) | 0.06 |
Renal disease | 0 | 11 (3.9) | — |
Esophageal dysmotility | 109 (38.9) | 139 (49.6) | 0.01 |
Cancer | 0 | 16 (5.7) | — |
Cardiovascular involvement | 21 (7.5) | 98 (35.0) | < 0.0001 |
Antiphospholipid syndrome | 11 (3.9) | 72 (25.7) | < 0.0001 |
Laboratory and immunoserological abnormalities | | | |
Anemia | 52 (18.5) | 63 (22.5) | 0.295 |
Thrombocytopenia | 19 (6.7) | 29 (10.3) | 0.173 |
Antiendothelial cell antibody positivity | 48 (17.1) | 94 (33.5) | < 0.0001 |
Anticardiolipin antibody positivity | 53 (18.9) | 98 (35.0) | < 0.0001 |
Anti-ß2-GPI antibody positivity | 42 (15.0) | 79 (28.2) | < 0.0001 |
Anti-SSA positivity | 92 (32.8) | 94 (33.5) | 0.42 |
Anti-dsDNA positivity | 2 (0.7) | 9 (3.2) | 0.06 |
Anti-Sm positivity | 10 (3.5) | 19 (6.7) | 0.125 |
ACPA positivity | 21/178** (11.7) | 53 (18.9) | 0.05 |